Graft-versus-lymphoma effects: Clinical review, policy proposals, and immunobiology

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 9, 2004, Pages 579-590

  Grigg, Andrew ^a   Ritchie, David ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

Author keywords

Graft versus lymphoma effects; Immunobiology

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DOXORUBICIN; FINGOLIMOD; FLUDARABINE; GALLIUM; HLA A1 ANTIGEN; HLA A2 ANTIGEN; MELPHALAN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

ALLOGRAFT; ALLOIMMUNITY; ANTIGEN EXPRESSION; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CANCER REGRESSION; EVIDENCE BASED MEDICINE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; IMMUNOBIOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MYCOSIS FUNGOIDES; POLICY; REVIEW; TREATMENT INDICATION; TUMOR RESISTANCE;

EID: 4344717337     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.05.008     Document Type: Editorial

References (105)

1. Bachier C.R. Giles R.E. Ellerson D. et al. Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma Leuk Lymphoma. 32 1999 279-288
2. Bierman P.J. Allogeneic bone marrow transplantation for lymphoma Blood Rev. 14 2000 1-13
3. Sureda A. Schmitz N. Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies Am J Hematol. 82 2003 1-13
4. Peniket A.J. Ruiz de Elvira M.C. Taghipour G. et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation Bone Marrow Transplant. 31 2003 667-678
5. Robinson S.P. Goldstone A.H. Mackinnon S. et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation Blood 100 2002 4310-4316
6. Ritchie D.S. Morton J. Szer J. et al. Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan Biol Blood Marrow Transplant. 9 2003 435-442
7. Khouri I.F. Saliba R.M. Giralt S.A. et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treated related mortality Blood 98 2001 3595-3599
8. Mandigers C.M.P.W. Meijerink J.P.P. Raemaekers J.M.M. et al. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18) Lancet 352 1998 1522-1523
9. Bernard M. Dauriac C. Drenou B. et al. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma Bone Marrow Transplant. 23 1999 329-333
10. Marks D.I. Lush R. Cavenagh J. et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation Blood 100 2002 3108-3114
11. Chakraverty R. Peggs K. Chopra R. et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen Blood 99 2002 1071-1078
12. Maris M.B. Niederwieser D. Sandmaier B.M. et al. Nonmyeloablative haematopoietic stem cell transplants (NMHSCT) using 10 HLA antigen matched unrelated donors (URDs) for patients (pts) with advanced hematologic malignancies Blood 100 11 2002 76a (abstr.)
13. Van Besien K. Khouri I. Champlin R. McCarthy P. Allogeneic transplantation for low grade lymphoma: long term follow-up J Clin Oncol. 18 2000 702-703
14. Forrest D.L. Thompson K. Nevill T.J. et al. Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma Bone Marrow Transplant. 29 2002 973-978
15. Hosing C. Saliba R.M. McLaughlin P. et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma Ann Oncol. 14 2003 737-744
16. Van Besien K. Loberiz F.E. Bajorunaite R. et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma Blood 10 2003 3521-3529
17. Bierman P.J. Sweetenham J.W. Loberiza F.R. et al. Syngeneic haematopoietic stem cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation J Clin Oncol. 20 2003 3744-3753
18. Schouten H.C. Qian W. Kvaloy S. et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial J Clin Oncol. 21 2003 3918-3927
19. Sweetenham J.W. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials? Bone Marrow Transplant. 28 2001 813-820
20. Grigg A. Bardy P. Byron K. et al. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma Bone Marrow Transplant. 23 1999 107-110
21. Khouri I.F. Meng-Sheng L. Romaguera J. et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy Ann Oncol. 10 1999 1293-1299
22. Sohn S.K. Baek J.H. Kim D.H. et al. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL Am J Hematol. 65 2000 75-80
23. Khouri I.F. Ming-Sheng L. Saliba R.M. et al. Nonablative allogeneic stem cell transplantation for advanced/recurrent mantle cell lymphoma J Clin Oncol. 21 2003 4407-4412
24. Khouri I.F. Saliba R.M. Okorohi G.-J. Acholonu S.A. Champlin R.E. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission Cancer 98 2003 2633-2634
25. Freedman A.S. Neuberg D. Gribben J.G. et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission J Clin Oncol. 16 1998 13-18
26. Khouri I.F. Saliba R. Hosing C. et al. Long-term follow-up of autologous stem cell transplantation in first remission in patients with diffuse mantle cell lymphoma Ann Oncol. 13suppl 2 2002 78
27. Romaguera J. Cabarillas F. Dang N. et al. Mantle cell lymphoma-update on results after R-HCVAD without stem cell transplant Ann Oncol. 13 suppl 2 2002 8
28. Rondon G. Giralt S. Huh Y. et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia Bone Marrow Transplant. 18 1996 669-672
29. Dreger P. Brand R. Hansz J. et al. Treatment-related mortality and graft versus leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning Leukemia 17 2003 842-848
30. Schetelig J. Thiede C. Bornhauser M. et al. Evidence of a graft versus leukemia effect in chronic lymphocytic leukemia after reduced intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group J Clin Oncol. 21 2003 2747-2753
31. Dreger P. Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia Leukemia 16 2002 985-992
32. Peggs K.S. Thomson K. Hart D.P. et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses Blood 103 2004 1548-1556
33. Peggs K.S. Thomson K. Chopra R. et al. Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: evidence of a therapeutically relevant graft-versus-lymphoma effect Blood 102 2003 198a (abstr.)
34. Porter D.L. Connors J.M. Van Deerlin V. et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies J Clin Oncol. 17 1999 1234-1243
35. Branson K. Chopra R. Panagiotis D. et al. Role of non-myeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies J Clin Oncol. 20 2002 4022-4031
36. Porter D.L. Luger S.M. Duffy K.M. et al. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation Biol Blood Marrow Transplant. 7 2001 230-238
37. Robinson S.P. Sureda A. Mackinnon S. et al. Reduced intensity allogeneic stem cell transplantation for Hodgkin's disease: an analysis from the European Group for Blood and Marrow Transplantation Blood 10011 2002 144a (abstr.)
38. Anderlini P. Acholonu S. Okoroji G.J. et al. Reduced early transplant-related mortality following allogeneic stem cell transplantation (SCT) with fludarabine-based, reduced-intensity conditioning from matched related and unrelated donors in advanced Hodgkin's disease (HD) Blood 100 11 2002 620a (abstr.)
39. Cooney J.P. Stiff P.J. Toor A.A. Parthasarathy M. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective Biol Blood Marrow Transplant. 9 2003 177-182
40. Gajewski J.L. Phillips G.L. Sobocinski K.A. et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease J Clin Oncol. 14 1996 572-578
41. Akpek G. Ambinder R.F. Piantadosi S. et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma J Clin Oncol. 19 2001 4314-4321
42. Milpied N. Fielding A.K. Pearce R.M. et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease J Clin Oncol. 14 1996 1291-1296
43. Carella A.M. Cavaliere M. Lerma E. et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma J Clin Oncol. 18 2000 3918-3924
44. Vandenberghe E. Pearce R. Taghipour G. et al. Role of a second transplant in the management of poor prognosis lymphomas: a report from the European Blood and Bone Marrow Registry J Clin Oncol. 15 1997 1595-1600
45. Espanol I. Buchler T. Ferra C. Gallardo D. Richter's syndrome after allogeneic stem cell transplantation for chronic lymphocytic leukaemia successfully treated by withdrawal of immunosuppression, and donor lymphocyte infusion Bone Marrow Transplant. 31 2003 215-218
46. Van Besien K.W. de Lima M. Giralt S.A. et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect Bone Marrow Transplant. 19 1997 977-982
47. Cesaro S. Messina C. Rosolen A. et al. Successful treatment of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation with donor lymphocyte infusion failed to prevent recurrence of primary disease: a case report Bone Marrow Transplant. 23 1999 625-628
48. Spitzer T.R. McAfee S. Sackstein R. et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies Biol Blood Marrow Transplant. 6 2000 309-320
49. Van Besien K.W. Mehra R.C. Giralt S.A. et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology Am J Med. 100 1996 299-307
50. Dhedin N. Giraudier S. Gaulard P. et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database Br J Haematol. 107 1999 154-161
51. Corradini P. Dodero A. Zallio F. et al. Nonmyeloablative conditioning followed by allogeneic transplantation has a better outcome than high-dose chemotherapy plus autografting in non-Hodgkin lymphomas with T-cell histology Blood 100 2002 427a (abstr.)
52. Shimoni A. Hardan I. Avigdor A. et al. Rituximab reduces relapse risk after allogeneic and autologous stem-cell transplantation in patients with high risk aggressive non-Hodgkin's lymphoma Br J Haematol. 122 2003 457-464
53. Levine J.E. Harris R.E. Fausto R. et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma Blood 101 2003 2476-2482
54. Chopra R. Goldstone A.H. Pearce R. et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data J Clin Oncol. 10 1992 1690-1695
55. Abraham R. Szer J. Bardy P. Grigg A.P. Early cyclosporin taper in high risk sibling allogeneic bone marrow transplants Bone Marrow Transplant. 20 1997 773-777
56. Grigg A.P. Seymour J.F. Graft versus Burkitt's lymphoma effect after allogeneic marrow transplantation Leuk Lymphoma. 43 2002 889-892
57. Mead G.M. Sydes M.R. Walewski J. et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY05 study Ann Oncol. 13 2002 1264-1274
58. Soligo D. Ibatici A. Berti E. et al. Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen Bone Marrow Transplant. 31 2003 663-666
59. Guitart J. Wickless S.C. Oyama Y. et al. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma Arch Dermatol. 138 2002 1359-1365
60. Fijnheer R. Sanders C.J.G. Canninga M.R. et al. Complete remission of a radiochemotherapy-resistant cutaneous T-cell lymphoma with allogeneic non-myeloablative stem cell transplantation Bone Marrow Transplant. 32 2003 345-347
61. Mapara M.Y. Kim Y.M. Marx J. Sykes M. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism Transplantation 76 2003 297-305
62. Mapara M.Y. Kim Y.M. Wang S.P. et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells Blood 100 2002 1903-1909
63. Teshima T. Ordemann R. Reddy P. et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium Nat Med. 8 2002 575-581
64. van den Brink M.R. Burakoff S.J. Cytolytic pathways in haematopoietic stem-cell transplantation Nat Rev Immunol. 2 2002 273-281
65. Bennett S.R. Carbone F.R. Toy T. et al. B cells directly tolerize CD8(+) T cells J Exp Med. 188 1998 1977-1983
66. Parekh V.V. Prasad D.V. Banerjee P.P. et al. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1 J Immunol. 170 2003 5897-5911
67. Skok J. Poudrier J. Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development J Immunol. 163 1999 4284-4291
68. Mori L. Loetscher K. Kakimoto H. et al. Expression of a transgenic T cell receptor beta chain enhances collagen-induced arthritis J Exp Med. 176 1992 381-388
69. Harris D.P. Haynes L. Sayles P.C. et al. Reciprocal regulation of polarized cytokine production by effector B and T cells Nat Immunol. 1 2000 475-482
70. Qin Z. Richter G. Schuler T. et al. B cells inhibit induction of T cell-dependent tumor immunity Nat Med. 4 1998 627-630
71. Watt V.A. Ronchese F. Ritchie D.S. Resting B cells impair antigen-specific tumour immunity via a MHC class-I independent mechanism Scand J Immunol. 58 2003 (abstr. J08)
72. Lapointe R. Bellemare-Pelletier A. Housseau F. et al. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells Cancer Res. 63 2003 2836-2843
73. Dotti G. Savoldo B. Yotnda P. et al. Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells Blood 100 2002 200-207
74. Dilloo D. Brown M. Roskrow M. et al. CD40 ligand induces an antileukemia immune response in vivo Blood 90 1997 1927-1933
75. Ritchie DS, Yang J, Hermans IF, Ronchese F. B Lymphocytes activated by CD40 ligand induce an antigen specific anti-tumor immune response by direct and indirect activation of CD8+ T cells. Scand J Immunol. In press.
76. Kennedy M.K. Mohler K.M. Shanebeck K.D. et al. Induction of B cell costimulatory function by recombinant murine CD40 ligand Eur J Immunol. 24 1994 116-123
77. Van-Dreese F.A. Boot H. Dellemijn T.A. et al. Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma Immunology 94 1998 580-586
78. Chaperot L. Plumas J. Jacob M.C. et al. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas Exp Hematol. 27 1999 479-488
79. Andersen N.S. Larsen J.K. Christiansen J. et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures Blood 96 2000 2219-2225
80. Hsu F.J. Benike C. Fagnoni F. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nat Med. 2 1996 52-58
81. Timmerman J.M. Czerwinski D.K. Davis T.A. et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients Blood 99 2002 1517-1526
82. Gitelson E. Hammond C. Mena J. et al. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines Clin Cancer Res. 9 2003 1656-1665
83. Hermans I.F. Ritchie D.S. Yang J. et al. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity J Immunol. 164 2000 3095-3101
84. Janssens W. Carlier V. Wu B. et al. CD4+ CD25+ T cells lyse antigen-presenting B cells by fas-fas ligand interaction in an epitope-specific manner J Immunol. 171 2003 4604-4612
85. Seliger B. Harders C. Wollscheid U. et al. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes Exp Hematol. 24 1996 1275-1279
86. Riemersma S.A. Jordanova E.S. Schop R.F. et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites Blood 96 2000 3569-3577
87. Alizadeh A. Eisen M. Davis R.E. et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes Cold Spring Harb Symp Quant Biol. 64 1999 71-78
88. Shipp M.A. Ross K.N. Tamayo P. et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat Med. 8 2002 68-74
89. Potsch C. Vohringer D. Pircher H. Distinct migration patterns of naive and effector CD8 T cells in the spleen: correlation with CCR7 receptor expression and chemokine reactivity Eur J Immunol. 29 1999 3562-3570
90. Baker M.B. Riley R.L. Podack E.R. et al. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function Proc Natl Acad Sci U S A 94 1997 1366-1371
91. Ghia P. Strola G. Granziero L. et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 Eur J Immunol. 32 2002 1403-1413
92. Kim Y.M. Sachs T. Asavaroengchai W. Bronson R. Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720 J Clin Invest. 111 2003 659-669
93. Lee R.S. Kuhr C.S. Sale G.E. et al. FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model Transplantation 76 2003 1155-1158
94. Staege M.S. Gisch K. Reske-Kunz A.B. Cytotoxic T cells with reciprocal antigenic peptide presentation function are not generally resistant to mutual lysis Immunol Cell Biol. 81 2003 266-274
95. Masood N. Russell K.J. Olerud J.E. et al. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation J Am Acad Dermatol. 47 2002 140-145
96. Billiau A.D. Fevery S. Rutgeerts O. et al. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants Blood 100 2002 1894-1902
97. Johnson B.D. Becker E.E. Truitt R.L. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets Biol Blood Marrow Transplant. 5 1999 123-132
98. Dey B.R. McAfee S. Colby C. et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor responses in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation Biol Blood Marrow Transplant. 9 2003 320-329
99. Edinger M. Hoffmann P. Ermann J. et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation Nat Med. 9 2003 1144-1150
100. Sato K. Yamashita N. Yamashita N. Baba M. Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse Immunity 18 2003 367-379
101. Anderson L.D. Mori S. Mann S. et al. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease Cancer Res. 60 2000 5797-5802
102. Zeis M. Steinmann J. Petrela E. et al. Transfer of idiotypic protein primed allogeneic marrow graft elicits potent graft-versus-myeloma effects in mice Bone Marrow Transplant. 27 2001 279-285
103. Teshima T. Liu C. Lowler K.P. et al. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation Cancer Res. 62 2002 796-800
104. Anderson L.D. Savary C.A. Mullen C.A. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease Blood 95 2000 2426-2433
105. Zoller M. Tumor vaccination after allogeneic bone marrow cell reconstitution of the nonmyeloablatively conditioned tumor-bearing murine host J Immunol. 171 2003 6941-6953